Tysabri (natalizumab)

pCPA File Number: 20792

Negotiation Status:

Concluded with an LOI

Indication(s):

Multiple Sclerosis, Relapsing-Remitting

Sponsor/Manufacturer:

Biogen Canada Inc.

CDA-AMC Project Number:

SR0133-000

pCPA Engagement Letter Issued:

2013-12-01

Negotiation Process Concluded:

2013-05-09